Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Future Directions In Esophageal Cancer Therapy.

Ori Wald, Brandon G Smaglo, Henry Mok, Shawn S. Groth
Published 2017 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Resection techniques for esophageal carcinoma continue to evolve, from endoscopic mucosal resection or endoscopic submucosal dissection for early stage disease to standard and robot-assisted minimally invasive esophagectomy as part of multimodal therapy for locally advanced disease. Though currently limited to assessing conduit perfusion and sentinel lymph nodes, embedded technology in the robotic surgical platform will likely play an expanded role during esophagectomy in the future. The use of targeted therapies, checkpoint inhibitors, engineered immune cell therapy, and cancer vaccines show promise in the treatment of systemic disease. Radiation therapy techniques are becoming increasingly sophisticated and they may play a more active role in stage IV disease in the future.
This paper references
10.1007/s00280-015-2799-3
Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer
S. Ueda (2015)
10.1001/JAMA.281.17.1623
Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group.
J. Cooper (1999)
10.1016/S0140-6736(10)61121-X
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Y. Bang (2010)
10.3748/WJG.V9.I1.9
Gene expression profiles at different stages of human esophageal squamous cell carcinoma.
J. Zhou (2003)
10.1200/JCO.2013.51.2186
Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials.
V. Oppedijk (2014)
10.1038/bjc.2015.460
Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma
LH McCormick Matthews (2015)
10.1136/gutjnl-2013-305372
British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus
R. Fitzgerald (2013)
10.3978/j.issn.2078-6891.2014.096
Endoscopic options for early stage esophageal cancer.
P. Shah (2015)
Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles.
C. Kihara (2001)
10.1007/s00464-008-9959-z
The first series of completely robotic esophagectomies with three-field lymphadenectomy: initial experience
K. Kernstine (2008)
10.3978/j.issn.2072-1439.2012.08.16
Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial.
O. Khan (2012)
The NCCN Clinical Practice Guidelines in Oncology TM Esophageal and Esophagogastric Junction Cancers ( Version 2 .
LQ Zhao (2016)
Chemoradiotherapy - panacea for esophageal cancer? Commentary for 'Chemoradiotherapy of locally advanced esophageal cancer. Long-term follow-up of a prospective randomized trial (RTOG 85-01)'
Syk Law (1999)
10.1200/JCO.2016.34.4_SUPPL.7
Updated results for the advanced esophageal carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab.
T. Doi (2016)
10.1200/JCO.2016.34.15_SUPPL.4050
Prospective randomized phase II study of concurrent chemoradiotherapy versus chemotherapy alone in stage IV esophageal squamous cell carcinoma.
T. Li (2016)
10.1200/JCO.2015.62.6598
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
J. R. Hecht (2016)
10.1517/13543784.2016.1163336
Emerging immunotherapy for the treatment of esophageal cancer
SeungJu Jackie Oh (2016)
10.1053/j.semtcvs.2015.10.006
Robotic Esophagectomy for Cancer: Early Results and Lessons Learned.
R. Cerfolio (2016)
10.1016/j.vaccine.2014.09.002
High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine.
T. Saito (2014)
10.1007/s00280-015-2854-0
Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma
J. Tian (2015)
10.1016/S1470-2045(14)70420-6
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
H. Wilke (2014)
10.4161/cbt.12.3.15949
Cancer-testis gene expression profiling in esophageal squamous cell carcinoma: Identification of specific tumor marker and potential targets for immunotherapy
M. Forghanifard (2011)
10.1158/1078-0432.CCR-14-1559
Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer
S. Kageyama (2015)
High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine
西塔 拓郎 (2015)
Global gene expression profiling in Barrett's esophagus and esophageal cancer: a 165 Annals of cardiothoracic surgery, Vol 6, No 2 March 2017 © Annals of Cardiothoracic Surgery
FM Selaru (2002)
10.1097/SLA.0b013e3182590603
Outcomes After Minimally Invasive Esophagectomy: Review of Over 1000 Patients
J. Luketich (2012)
10.1200/JCO.2016.34.15_SUPPL.4009
Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity.
H. Chung (2016)
10.1016/S1470-2045(14)70024-5
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.
S. Dutton (2014)
10.1016/S1470-2045(15)00040-6
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
J. Shapiro (2015)
10.1158/1078-0432.CCR-15-0600
FDA Approval Summary: Ramucirumab for Gastric Cancer
S. Casak (2015)
10.1007/s00464-013-2915-6
Initial experience from a large referral center with robotic-assisted Ivor Lewis esophagogastrectomy for oncologic purposes
S. Fuente (2013)
10.2147/CMAR.S35785
Nedaplatin: a cisplatin derivative in cancer chemotherapy
M. Shimada (2013)
10.1038/sj.onc.1209357
Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis
S. Wang (2006)
10.1016/j.gtc.2015.02.006
Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection for Endoscopic Therapy of Barrett's Esophagus-related Neoplasia.
S. Kothari (2015)
10.1038/bjc.2015.342
Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma
Nadeera de Silva (2015)
10.1245/s10434-015-4440-4
Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer
T. Miyazaki (2015)
10.1200/JCO.20.5.1167
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.
B. Minsky (2002)
10.1016/j.jtcvs.2016.04.025
Safety and feasibility of near-infrared image-guided lymphatic mapping of regional lymph nodes in esophageal cancer.
Krista J. Hachey (2016)
10.18632/oncotarget.5959
S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study
Y. Li (2015)
10.1186/1479-5876-11-246
Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients
S. Kageyama (2013)
10.1186/1479-5876-12-84
Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients
H. Iinuma (2013)
10.1097/imi.0000000000000091
Intraoperative Near-Infrared Fluorescence Imaging as an Adjunct to Robotic-Assisted Minimally Invasive Esophagectomy
I. Sarkaria (2014)
10.1111/cas.12894
Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial
M. Lu (2016)
10.1111/cas.12764
Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604)
M. Tahara (2015)
10.1016/j.jtcvs.2012.10.031
Gene expression profiles in esophageal adenocarcinoma predict survival after resection.
A. Pennathur (2013)



This paper is referenced by
10.1111/cas.13481
Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study
K. Kato (2018)
10.1111/1759-7714.12874
Clinical complete response after chemoradiotherapy for carcinoma of thoracic esophagus: Is esophagectomy always necessary? A systematic review and meta‐analysis
J. Wang (2018)
10.1101/19010835
Impact of Radiation on Cardiovascular Outcomes in Patients with Resectable Esophageal Cancer
R. Sarkar (2019)
10.1021/ACS.OPRD.7B00103
Synthesis of Tegafur by the Alkylation of 5-Fluorouracil under the Lewis Acid and Metal Salt-Free Conditions
A. Zasada (2017)
10.3390/genes10110927
The Critical Role of Hypoxic Microenvironment and Epigenetic Deregulation in Esophageal Cancer Radioresistance
Catarina Macedo-Silva (2019)
10.1002/path.5528
GRB7 is an oncogenic driver and potential therapeutic target in oesophageal adenocarcinoma
Jovana R Gotovac (2020)
10.1002/path.5142
Clonal distribution and intratumour heterogeneity of the B‐cell repertoire in oesophageal squamous cell carcinoma
Chaoting Zhang (2018)
10.1158/1541-7786.MCR-19-1152
RCC2 Promotes Esophageal Cancer Growth by Regulating Activity and Expression of the Sox2 Transcription Factor
Ali J. Calderon-Aparicio (2020)
10.1016/j.ebiom.2019.05.023
Sub-region based radiomics analysis for survival prediction in oesophageal tumours treated by definitive concurrent chemoradiotherapy
C. Xie (2019)
10.1093/carcin/bgy116
Immediate and substantial evolution of T-cell repertoire in peripheral blood and tumor microenvironment of patients with esophageal squamous cell carcinoma treated with preoperative chemotherapy
Chaoting Zhang (2018)
10.1111/1759-7714.12771
Practical value of identifying circulating tumor cells to evaluate esophageal squamous cell carcinoma staging and treatment efficacy
Weipeng Chen (2018)
10.2217/fon-2019-0024
Comparison of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for esophageal cancer: a meta-analysis.
Shao-wu Jing (2019)
10.3389/fcell.2020.00649
Identification of a TLR-Induced Four-lncRNA Signature as a Novel Prognostic Biomarker in Esophageal Carcinoma
J. Liu (2020)
Semantic Scholar Logo Some data provided by SemanticScholar